Senior Director, Market Development

Position Overview

Immunome is seeking a Senior Director, U.S. Market Development to lead and provide strategic direction for commercial market development activities in preparation for the potential launch of varegacestat in desmoid tumors. This role will be responsible for shaping the U.S. commercial and clinical landscape ahead of launch by building strategic relationships with key opinion leaders (KOLs), generating actionable market insights, and translating those insights into launch strategy. The Senior Director will ensure the U.S. market is informed, aligned, and ready for varegacestat at approval. 

As a senior member of the U.S. Commercial organization, this individual will partner cross-functionally with Sales, Marketing, Market Access, Medical Affairs, Clinical Development, and HEOR to ensure launch plans are grounded in real-world insights and reflect the evolving treatment paradigm in desmoid tumors. The mission of this role is to help position varegacestat for strong adoption by establishing Immunome as a trusted commercial and scientific partner within the U.S. desmoid tumor community. 

Responsibilities

U.S. Market Development & Launch Readiness 

• Lead the development and execution of the U.S. market development strategy for varegacestat, aligned with commercial launch objectives. 

• Define, prioritize, and implement pre-launch initiatives that prepare the market for approval and early adoption. 

• Identify and proactively address barriers to uptake, including referral patterns, treatment sequencing dynamics, and care setting variability. 

• Provide senior-level strategic input into: 

• • U.S. positioning and messaging. 

• • Target product profile refinement. 

• • Disease awareness initiatives. 

• • Field force strategy and engagement model. 

• Partner closely with Marketing and Sales leadership to drive alignment and ensure launch readiness milestones are met. 

U.S. KOL Strategy & Commercial Engagement 

• Lead the mapping, segmentation, and prioritization of U.S. KOLs and high-impact treatment centers across academic and community settings. 

• Build and sustain credible, compliant relationships with leading desmoid tumor experts, sarcoma specialists, and multidisciplinary stakeholders. 

• Lead commercial KOL engagement through: 

• • 1:1 strategic discussions. 

• • U.S. advisory boards. 

• • Regional roundtables. 

• • National congress engagement (ASCO, CTOS, SSO, etc.). 

• Ensure insights from engagements are systematically captured and translated into actionable strategic commercial recommendations. 

Insight Generation & Competitive Intelligence 

• <